Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578683 | 0.85 | KDM4E (0.71) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL123193 | 0.83 | ALDH1A1 (0.69) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL29405887 | 0.83 | ALDH1A1 (0.69) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL29196640 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1573605 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8505033 | 0.82 | ALDH1A1 (0.67) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5266634 | 0.82 | ALDH1A1 (0.67) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL657598 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1327792 | 0.82 | ALDH1A1 (0.67) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1573603 | 0.82 | KDM4E (0.67) | KDM4EALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391916-B1 | ANTITUMOR AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2002-05-21 | — | — | US | claimed |
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20230099775-A1 | CURABLE COMPOSITION, CURED PRODUCT, CURED FILM, DISPLAY PANEL, AND METHOD FOR PRODUCING CURED FILM | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20230064254-A1 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| WO-1996030395-A2 | CYSTEINE PROTEASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-03 | — | — | WO | disclosed |
| US-5470714-A | One-step free fatty acid determination method | LIDAK PHARMACEUTICALS (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0457901-B1 | FREE FATTY ACID DETERMINATION | LIDAK PHARMACEUTICALS (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0457901-A4 | FREE FATTY ACID DETERMINATION | — | 1992-06-10 | — | — | EP | disclosed |
| EP-0457901-A1 | FREE FATTY ACID DETERMINATION. | LIDAK PHARMACEUTICALS (US) | 1991-11-27 | — | — | EP | disclosed |
| WO-1991009310-A1 | FREE FATTY ACID DETERMINATION | LIDAK PHARMACEUTICALS (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4537718-A | GLUTATHIONE JOINED BY LINKAGE GROUPS TO A SECTROSCOPIC REPORTER | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0069397-B1 | ELECTROPHOTOGRAPHIC PLATE | MITSUBISHI KASEI CORPORATION (JP) | 1985-02-20 | — | — | EP | disclosed |
| US-4407919-A | UNSATURATED NITRILES IN CHARGE TRANSPORTATION LAYER | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1983-10-04 | — | — | US | disclosed |
| EP-0069397-A1 | Electrophotographic plate | MITSUBISHI KASEI CORPORATION (JP) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | KDM4E 1885/4885ALDH1A1 2259/4885GAA 3698/4885 |
| US-20230064254-A1 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | GNAQ, REN, GLS | KDM4E 4097/4885ALDH1A1 3279/4885GAA 524/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | KDM4E 3461/4885ALDH1A1 1049/4885GAA 1709/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | KDM4E 570/4885ALDH1A1 235/4885GAA 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.